Oncolytics Biotech Inc (ONCY) Stock AnalysisONCYOncolytics Biotech Inc

Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company developing pelareorep, a well-tolerated intravenously delivered immunotherapeutic agent that selectively replicates in RAS-mutated tumors and activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a range of oncology treatments. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically cold tumors hot through the activation of innate and adaptive immune responses. The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Oncolytics Biotech Inc is a good buy right now due to its recent patent acquisition and FDA Fast Track designation, which enhance its market position. The current price is $0.86, and the RSI is at 61.82, indicating bullish momentum. However, the company has reported significant losses, with a net income of -12,679,060.40 CAD in Q1 2026, which poses a risk to its financial stability.